Item Details
19 Nov 2026

AbbVie agrees cancer research partnership worth up to $2.54 billion

Announced on 19 November, pharmaceutical group AbbVie has agreed a research and development partnership with German biotechnology company Disco Pharmaceuticals. The agreement includes $40 million upfront and up to $2.5 billion in milestone payments, alongside royalties, to develop advanced cancer treatments. HPC could identify biotechnology companies, pharmaceutical partners and investors interested in similar licensing and research opportunities.


If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.

AbbVie agrees cancer research partnership worth up to $2.54 billion

Get in Touch

We’ll get back to you shortly.